Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer

BACKGROUND: Anaplastic thyroid cancer is the most aggressive thyroid cancer and has a poor prognosis. At present, there is no effective treatment for it. METHODS: Here, we used different concentrations of GSK-J4 or a combination of GSK-J4 and doxorubicin to treat human Cal-62, 8505C, and 8305C anapl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Bo, Lu, Bing, Hsieh, I-yun, Liang, Zhen, Sun, Zicheng, Yi, Yang, Lv, Weiming, Zhao, Wei, Li, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239034/
https://www.ncbi.nlm.nih.gov/pubmed/32477122
http://dx.doi.org/10.3389/fphar.2020.00632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239034/
https://www.ncbi.nlm.nih.gov/pubmed/32477122
http://dx.doi.org/10.3389/fphar.2020.00632

Ejemplares similares